In this study, researchers assessed pediatric liver transplantation for metabolic disease in a large national cohort. The team sought to determine whether smaller studies suggesting a survival advantage for these recipients could be corroborated.
The team also investigated whether higher survival rates in recipients with metabolic disease are associated with lack of structural liver disease. They evaluated the recipients' risk factors for mortality.
They used Data from the Scientific Registry of Transplant Recipients to analyze results of pediatric liver transplantation for patients with biliary atresia and metabolic disease.
|Survival rates for children with metabolic disease at 1 and 5 years were 94% and 92%, respectively.|
|American Journal of Transplantation|
The team’s findings are published the March issue of American Journal of Transplantation.
The researchers found that adjusted survival rates for children with metabolic disease at 1 and 5 years were 94% and 92%, respectively. This was significantly higher than for recipients with biliary atresia, 90% and 86%, respectively.
Cox regression models identified recipient black race (relative risk (RR) = 5.1), and simultaneous transplantation of other organs (RR = 3.2), as significant risk factors for mortality in the metabolic group.
In addition, adjusted survival rates for metabolic patients with structural and nonstructural liver diseases were similar to each other at both 1 and 5 years.
Dr Liise Kaylera’s team concluded, “Children with metabolic disease had significantly higher adjusted short- and long-term post-transplant survival rates than those with biliary atresia”.
“Structural disease was not a risk factor for worse outcomes.”